Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulus Rises On HCV Data, But Will Injection Find A Market?

This article was originally published in Scrip

Executive Summary

Regulus Therapeutics Inc. reported positive interim Phase II results for its microRNA-targeting injection RG-101 in a hepatitis C virus (HCV) market that's dominated by highly effective oral drugs, but the company may be able to reach a goal that's been illusive for Gilead Sciences Inc. and its competitors – curing HCV patients with a four-week regimen.

You may also be interested in...



Finance Watch: Regulus Shrinks To Preserve Cash, Ironwood Cuts Jobs Ahead Of Split

Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.

Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree

The micro-RNA-focused biotech believes the jaundice seen with HCV candidate RG-101 was specific to the drug, not the target or delivery system, but is switching focus to other promising programs, such RG-012 for Alport syndrome.

Regulus RNAi Candidate Can Reduce HCV Treatment To Four Weeks

Although it is on FDA clinical hold to resolve safety concerns about jaundice, RG-101 has shown the ability to significantly reduce the length – and perhaps cost – of HCV therapy when combined with current direct-acting antivirals.

Related Content

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel